Anamorelin Study Published on Predictors of Response in Cancer Cachexia

A new publication on anamorelin appeared on August 3, 2026, in the International Journal of Clinical Pharmacology and Therapeutics. The study is titled "Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study." Anamorelin remains classified as an unapproved research compound. The publication is listed with PubMed identifier 42544527. This entry represents a new addition to the scientific literature on anamorelin as recorded on the given date. No findings, outcomes, or conclusions from the study have been detailed in this notice. The publication's scope, as indicated by its title, concerns factors related to discontinuation and response patterns among patients with cancer cachexia in a retrospective analysis. No dosing information, efficacy claims, or safety conclusions are included here, as none were provided beyond the title and journal listing. Readers interested in the specifics of the methodology or results should consult the original publication directly through the provided source link. For general background on anamorelin, including its regulatory status and research context, readers can refer to the compound overview.